News

Nanoworx
Second Project Funding Round of PharmaNL Shared Development Infrastructure Launches
September 12, 2024

The project “Nanoworx,” led by Prof. Dr. Willem Mulder, will soon commence under the PharmaNL Shared Development Infrastructure program. Projects in this program aim to establish infrastructure provisions for groundbreaking pharmaceutical products and drug development technologies.

PharmaNL Presents Investment Agenda: Roadmap for a Stronger Pharmaceutical Future
August 22, 2024

PharmaNL today publishes the PharmaNL Investment Agenda, a roadmap for targeted investments in educational opportunities to strengthen the Dutch pharmaceutical value chain. Based on a gap analysis and expert session, the Investment Agenda identifies key themes for future grant calls under the PharmaNL program. The next grant call will focus on the new funding round […]

First Project Funding Round of PharmaNL Shared Development Infrastructure Launches
August 15, 2024

In the coming months, the first project ‘G2 Solutions’ will start under the leadership of Prof. Dr. Ir. Floris Foijer within the PharmaNL Shared Development Infrastructure program line. Projects within this program focus on establishing infrastructure provisions for groundbreaking pharmaceutical products and technologies for drug development. Objective of the Funding Round The PharmaNL Shared Development […]

vacature programmamanager PharmaNL
Vacature: Algemeen Programmamanager PharmaNL
July 10, 2024

Inleiding PharmaNL is een initiatief van en voor de Nederlandse farmaceutische sector, gedragen door een landelijk publiek-privaat consortium bestaande uit Leiden University/Leiden University Medical Center, Campus Groningen en Pivot Park Oss. Dit programma heeft een looptijd van 8 jaar. PharmaNL is een toegekend groeifonds en heeft als ambitie een duurzame impuls te geven aan het […]

Ambitions become reality for talent development in life sciences with PharmaNL subsidy
March 25, 2024

The first subsidies in the program line Human Capital Growth of PharmaNL were awarded in February 2024. The consortium of the HAN University of Applied Sciences (HAN), Radboud University (RU), and Elevate is one of the first two successful applicants. For their project ‘Early Drug Discovery Education Track’, they received a subsidy of €250,000 from […]

Urgency: Investing in Innovation
March 15, 2024

The Importance of the National Growth Fund for the Earning Capacity of the Netherlands The Board of PharmaNL sent a letter to the House of Representatives on March 15, 2024 (specifically to the members of the VVD faction and NSC faction), expressing concern about the considerations surrounding the National Growth Fund. Brigitte Drees (lead of […]

Two projects will start within PharmaNL Human Capital Growth
February 20, 2024

In the coming months, the first two projects will commence within the Human Capital Growth program line of PharmaNL. These projects are the ‘Early Drug Discovery Education Track’ and ‘Groningen Human Capital for Life Sciences’. These two new projects focus specifically on developing flexible post-HBO and post-academic ‘lifelong learning’ education that aligns with developments in […]

PharmaNL launches multi-year ‘Shared Development Infrastructure’ subsidy program of 57 million euros
November 10, 2023

PharmaNL, an initiative for the Dutch pharmaceutical sector, is launching the ‘Shared Development Infrastructure’ subsidy program. The aim of this program is to further develop and make the existing infrastructure for the development of promising innovative pharmaceutical products and production technologies in the Netherlands more accessible. PharmaNL is making 57 million euros available for this […]

PharmaNL initiates a multi-year ‘Human Capital Growth’ subsidy program totaling 14 million euros.
September 5, 2023

Utrecht, 5 September 2023 - PharmaNL, an initiative for the Dutch pharmaceutical sector, is launching the 'Human Capital Growth' subsidy program. The objective of this program is to establish a cohesive and hybrid lifelong learning program, enhancing the current pharmaceutical education offerings and potentially endowing them with international appeal and attractiveness.